CB010A is a study for adults with a type of cancer called relapsed/refractory B cell non-Hodgkin lymphoma (NHL). This study uses a treatment called CAR-T cell therapy, which involves changing a person's T cells (a type of white blood cell) to better fight cancer. The process uses CRISPR, a tool that can edit genes, to help the cells work better. Participants will first have a process called lymphodepletion, where medicines like cyclophosphamide and fludarabine prepare their body for the new cells. The trial is in Phase 1, which means it is the first time this treatment is being tested in humans to see if it is safe and if it might work.

Key Points:

• The study has two parts: an initial dose test and a follow-up to see how well the dose works.
• Participants must be 18 or older with relapsed or refractory NHL and meet specific health criteria.
• Patients will not be eligible if they have had certain previous treatments or health issues.